Abstract
PCR-based preemptive therapy with ganciclovir has been shown to reduce the incidence of CMV disease after BMT. Failures of this treatment strategy are CMV disease and secondary non-viral infections. Eighty-six consecutive patients at high risk for CMV disease who received PCR-based preemptive therapy with ganciclovir were assessed for treatment failures and possible risk factors. Ganciclovir was initiated in 57 of 86 patients (66%). Only 28 of 86 (32%) patients received 4 or more weeks of ganciclovir. Recurrence of CMV infection after successful treatment was more frequent among recipients of a BMT from an unrelated compared to a sibling donor (P = 0.004). three (3.5%) patients developed non-fatal early onset cmv disease and seven of 68 (10.3 %) late onset cmv disease (>100 days post transplant). Risk factors for late onset CMV disease were cGVHD (P = 0.0017) and duration of prior antiviral therapy >4 weeks (P = 0.0073). The incidence of secondary non-viral infections was 28% with the duration of antiviral treatment being a significant risk factor for secondary bacterial (P = 0.0045) and invasive fungal infections (P = 0.006). Thus, PCR-based preemptive treatment with ganciclovir reduces early onset CMV disease, but the duration of antiviral therapy prior to day +100 is a significant risk factor for late onset CMV disease as well as secondary non-viral infections. Bone Marrow Transplantation (2000) 25, 757–763.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human bone marrow transplantation J Infect Dis 1986 153: 478–488
Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic BMT Ann Intern Med 1993 118: 173–178
Winston DJ, Winston GH, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Ann Intern Med 1993 118: 179–184
Schmidt GM, Horac DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants New Engl J Med 1991 324: 1005–1011
Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation New Engl J Med 1991 325: 1601–1607
Van der Bij W, Schirm J, Torensma R et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes J Med Virol 1988 25: 179
Jiwa JM, Van Gemert GW, Raap AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction Transplantation 1989 48: 72–76
Einsele H, Steidle H, Vallbracht A et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique Blood 1991 77: 1104–1110
Einsele H, Ehninger G, Steidle M et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease Lancet 1991 338: 1170–1172
Bacigalupo A, Van Lint MT, Tedone E et al. Early treatment of CMV infection in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir Bone Marrow Transplant 1994 13: 753–758
Boeckh M, Bowden RA, Goodrich J et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic bone marrow transplantation Blood 1992 80: 1358–1364
Ljungman P, Lore K, Aschan J et al. Use of a semiquantitative PCR assay for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients Bone Marrow Transplant 1996 17: 583–587
Einsele H, Ehninger G, Hebart H et al. PCR-monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy Blood 1995 86: 2815–2820
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors Transplantation 1974 18: 295–304
Lanino E, Anasetti C, Longton G et al. Prevention of cytomegalovirus disease with ganciclovir in recipients of marrow transplants from unrelated donors Blood 1993 82: (Suppl. 1) 1359 (Abstr.)
Li CR, Greenberg PD, Gilbert MJ et al. HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 1994 83: 1971–1979
Canpolat C, Culbert S, Gardner M et al. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients Bone Marrow Transplant 1996 17: 589–593
Przepiorka D, Ippoliti C, Panina J et al. Ganciclovir three times per week is not adequate to prevent CMV reactivation after T-cell depleted marrow transplantation Bone Marrow Transplant 1994 13: 461–464
Atkinson K, Arthur C, Bradstock K et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients Bone Marrow Transplant 1995 16: 401–405
Mandanas R, Saez RA, Selby GB, Confer DL . Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy Am J Hematol 1996 51: 104–111
Limaye AP, Bowden RA, Myerson D, Boeckh M . Cytomegalovirus disease occurring before engraftment in marrow transplant recipients Clin Infect Dis 1997 24: 830–835
Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063–4071
Yuen KY, Lo SKF, Chiu EKW et al. Monitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR J Clin Microbiol 1995 33: 2530–2534
Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 1999 93: 1781–1782
Boeckh M, Riddell SR, Cunningham T et al. Increased risk of late onset CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses Blood 1996 88: (Suppl. 1) 302a (Abstr. 1195)
Zaia JA, Gallez-Hawkins GM, Tegtmeier BR et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma J Infect Dis 1997 176: 782–785
Singhal S, Mehta J, Powles R . Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet Blood 1994 84: 2055–2056
Bowden RA, Digel J, Reed EC, Meyers JD . Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses J Infect Dis 1985 156: 899–903
Krause H, Hebart H, Jahn G et al. Screening for CMV-specific T-cell proliferation to identify patients at risk to develop late onset CMV disease Bone Marrow Transplant 1997 19: 1111–1116
Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 1992 257: 238–241
Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor New Engl J Med 1996 333: 1038–1044
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft (DFG), SFB 510, project B3.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Einsele, H., Hebart, H., Kauffmann-Schneider, C. et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 25, 757–763 (2000). https://doi.org/10.1038/sj.bmt.1702226
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702226
Keywords
This article is cited by
-
Cryptococcal meningitis
Nature Reviews Disease Primers (2023)
-
CMV infection is a risk factor for hemorrhagic cystitis after hematopoietic stem cell transplantation
Annals of Hematology (2023)
-
CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies
Current Treatment Options in Infectious Diseases (2021)
-
Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants
Bone Marrow Transplantation (2018)
-
Immunotherapy for viral and fungal infections
Bone Marrow Transplantation (2015)